Response by Pasupathy et al to Letters Regarding Article, "early Use of N-acetylcysteine (NAC) with Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction])"

Sivabaskari Pasupathy; Rosanna Tavella; John F. Beltrame

doi:10.1161/CIRCULATIONAHA.117.032512

Response by Pasupathy et al to Letters Regarding Article, "early Use of N-acetylcysteine (NAC) with Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction])"

Sivabaskari Pasupathy, Rosanna Tavella, John F. Beltrame

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Abstract

We appreciate the correspondence concerning the NACIAM trial (N-acetylcysteine in Acute Myocardial Infarction),¹ which focused on the study analytical methods and potential mechanisms contributing to the benefits of N-acetylcysteine (NAC)/nitroglycerin use in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

Original language	English
Pages (from-to)	1424-1425
Number of pages	2
Journal	Circulation
Volume	137
Issue number	13
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.117.032512
Publication status	Published - 27 Mar 2018
Externally published	Yes

Keywords

N-acetylcysteine
Primary percutaneous coronary intervention
Myocardial infarction

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/CIRCULATIONAHA.117.032512Licence: In Copyright

Fingerprint

Dive into the research topics of 'Response by Pasupathy et al to Letters Regarding Article, "early Use of N-acetylcysteine (NAC) with Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction])"'. Together they form a unique fingerprint.

Cite this

Pasupathy, S., Tavella, R., & Beltrame, J. F. (2018). Response by Pasupathy et al to Letters Regarding Article, "early Use of N-acetylcysteine (NAC) with Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction])". Circulation, 137(13), 1424-1425. https://doi.org/10.1161/CIRCULATIONAHA.117.032512

Pasupathy, Sivabaskari ; Tavella, Rosanna ; Beltrame, John F. / Response by Pasupathy et al to Letters Regarding Article, "early Use of N-acetylcysteine (NAC) with Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction])". In: Circulation. 2018 ; Vol. 137, No. 13. pp. 1424-1425.

@article{435be29fc5664769b4ed22b4c35247eb,

title = "Response by Pasupathy et al to Letters Regarding Article, {"}early Use of N-acetylcysteine (NAC) with Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction]){"}",

abstract = "We appreciate the correspondence concerning the NACIAM trial (N-acetylcysteine in Acute Myocardial Infarction),1 which focused on the study analytical methods and potential mechanisms contributing to the benefits of N-acetylcysteine (NAC)/nitroglycerin use in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.",

keywords = "N-acetylcysteine, Primary percutaneous coronary intervention, Myocardial infarction",

author = "Sivabaskari Pasupathy and Rosanna Tavella and Beltrame, {John F.}",

year = "2018",

month = mar,

day = "27",

doi = "10.1161/CIRCULATIONAHA.117.032512",

language = "English",

volume = "137",

pages = "1424--1425",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams & Wilkins",

number = "13",

}

Pasupathy, S, Tavella, R & Beltrame, JF 2018, 'Response by Pasupathy et al to Letters Regarding Article, "early Use of N-acetylcysteine (NAC) with Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction])"', Circulation, vol. 137, no. 13, pp. 1424-1425. https://doi.org/10.1161/CIRCULATIONAHA.117.032512

Response by Pasupathy et al to Letters Regarding Article, "early Use of N-acetylcysteine (NAC) with Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction])". / Pasupathy, Sivabaskari; Tavella, Rosanna; Beltrame, John F.
In: Circulation, Vol. 137, No. 13, 27.03.2018, p. 1424-1425.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Response by Pasupathy et al to Letters Regarding Article, "early Use of N-acetylcysteine (NAC) with Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (The NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction])"

AU - Pasupathy, Sivabaskari

AU - Tavella, Rosanna

AU - Beltrame, John F.

PY - 2018/3/27

Y1 - 2018/3/27

N2 - We appreciate the correspondence concerning the NACIAM trial (N-acetylcysteine in Acute Myocardial Infarction),1 which focused on the study analytical methods and potential mechanisms contributing to the benefits of N-acetylcysteine (NAC)/nitroglycerin use in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

AB - We appreciate the correspondence concerning the NACIAM trial (N-acetylcysteine in Acute Myocardial Infarction),1 which focused on the study analytical methods and potential mechanisms contributing to the benefits of N-acetylcysteine (NAC)/nitroglycerin use in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

KW - N-acetylcysteine

KW - Primary percutaneous coronary intervention

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=85053863098&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.117.032512

DO - 10.1161/CIRCULATIONAHA.117.032512

M3 - Letter

C2 - 29581375

AN - SCOPUS:85053863098

SN - 0009-7322

VL - 137

SP - 1424

EP - 1425

JO - Circulation

JF - Circulation

IS - 13

ER -